Novocure: Steady Ahead of Key Milestones
Here's our initial take on 's (NASDAQ: NVCR) fiscal 2025 second-quarter financial report.
Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both revenue and loss per share topping Wall Street expectations. The company, which is developing noninvasive methods to treat solid-tumor cancers, has added more than 300 active patients to its trials over the last year.
Revenue from its Optune Lua lung cancer treatment, which was approved for use in the U.S. last fall, totaled $2.4 million.
Source Fool.com
Novocure Ltd Aktie
10,12 €
-1,16 %
